"Sometimes, there is more than a single answer to a question; this certainly applies to patients with benign prostatic disease," writes Gopal H. Badlani, MD. The Society of Benign Prostatic Disease ...

“We took the urine from those patients, and we tested to see if we can predict their gemcitabine metabolism capability. We were able to predict it pretty accurately,” says Laura Bukavina, MD, MPH. In ...

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23 ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Hear insights from experts on key trial data presented at ASCO GU 2025. In this video, Urology Times® highlights 5 interviews on key trial data presented at the 2025 American Society of Clinical ...

"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding ...

Panelists discuss how PD-L1 inhibitors such as durvalumab and sasanlimab represent a promising frontier in non–muscle-invasive bladder cancer (NMIBC) treatment. These immunotherapies work by ...

“It shows the significant poor outcomes in this population with our standard therapies and the need to improve upon that by developing novel treatments,” says Darren R. Feldman, MD. In this video, ...

In this video, Kate H. Gessner, MD, PhD, discusses the mechanisms of immunotherapy failure in renal cell carcinoma, which was discussed during a case-based session at the 2025 American Society of ...

Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the ...

WOLVERINE meta-analysis indicates MDT improves survival outcomes in oligometastatic prostate cancer, enhancing PFS, rPFS, and CRFS compared to SOC alone. The study included 472 patients, with a median ...